A Case of Anti-Cyclic Citrullinated Peptide Antibody-Positive Rheumatoid Arthritis Following Peginterferon Alpha-2A and Ribavirin Therapy for Chronic Hepatitis C.
- Author:
Dong Hyun KIM
1
;
Young Hwan KIM
;
Soon Il LEE
;
Byung Kil HA
;
Sung Ho CHOI
;
Sung Il KIM
;
Joung Wook LEE
Author Information
1. Department of Internal Medicine, Busan St. Mary's Medical Center, Busan, Korea. gesundheit@paran.com
- Publication Type:Case Report
- Keywords:
Arthritis, Rheumatoid;
Hepatitis C, Chronic;
Peginterferon alpha-2a
- MeSH:
Antibodies;
Arthritis;
Arthritis, Rheumatoid;
Autoimmune Diseases;
Female;
Hepatitis;
Hepatitis C;
Hepatitis C, Chronic;
Hepatitis, Chronic;
Humans;
Interferons;
Middle Aged;
Ribavirin;
Thyroid Diseases
- From:Korean Journal of Medicine
2012;83(2):287-290
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Combination therapy with pegylated interferon (IFN) and ribavirin is the mainstay of treatment for chronic hepatitis C. An important side effect of IFN is the induction of an autoimmune disease such as autoimmune thyroid disease or, rarely, rheumatoid arthritis. However, the introduction of pegylated formulations of IFN can minimize the risk of autoimmune induction by reducing immunogenicity. Detection of anti-cyclic citrullinated peptide (anti-CCP) antibodies can help distinguish rheumatoid arthritis from hepatitis C-related arthritis. Here, we report the first Korean case of a 48-year-old female who developed anti-CCP antibody-positive rheumatoid arthritis following peginterferon alpha-2a therapy for hepatitis C.
